| Date Filed | Type | Description |
| 10/13/2023 |
8-K
| Quarterly results |
| 10/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/06/2023 |
4
| ROBERTS BRIAN KENNETH (Chief Medical Officer) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Bought 5,000 shares
@ $1.8999, valued at
$9.5k
|
|
| 06/02/2023 |
8-K
| Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics, Financial Statements and Exhib... |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
SC 13D/A
| Genexine Inc. reports a 5% stake in Rezolute, Inc. |
| 02/14/2023 |
SC 13G
| FIRST MANHATTAN CO reports a 8.5% stake in Rezolute, Inc. |
| 02/14/2023 |
SC 13G/A
| CAXTON CORP reports a 5% stake in Rezolute, Inc. |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2023 |
10-Q
| Quarterly Report for the period ended December 31, 2022 |
| 02/10/2023 |
8-K
| Quarterly results |
| 02/01/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/13/2023 |
8-K
| Quarterly results |
| 12/15/2022 |
8-K
| Quarterly results |
| 11/09/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 11/07/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 10/28/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 09/15/2022 |
10-K
| Annual Report for the period ended June 30, 2022 |
| 09/15/2022 |
8-K
| Quarterly results |
| 07/05/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 07/01/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 07/01/2022 |
8-K
| Quarterly results |
| 06/28/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 06/28/2022 |
4
| Kim Young-Jin (Director) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 40,000 options to buy
@ $3.4, valued at
$136k
|
|
| 06/27/2022 |
4
| FAUCHET PHILIPPE (Director) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 80,000 options to buy
@ $3.4, valued at
$272k
|
|
| 06/27/2022 |
4
| ROBERTS BRIAN KENNETH (Sr VP, Clinic Development) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 700,000 options to buy
@ $3.4, valued at
$2.4M
|
|
| 06/27/2022 |
4
| Hogenhuis Wladimir (Director) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 80,000 options to buy
@ $3.4, valued at
$272k
|
|
| 06/27/2022 |
4
| Elam Nevan C (CEO) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 2,600,000 options to buy
@ $3.4, valued at
$8.8M
|
|
| 06/27/2022 |
4
| Labrucherie Gil M (Director) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 80,000 options to buy
@ $3.4, valued at
$272k
|
|
| 06/27/2022 |
4
| KREHER NERISSA (Director) has filed a Form 4 on Rezolute, Inc.|
Txns:
| Granted 80,000 options to buy
@ $3.4, valued at
$272k
|
|
| 06/27/2022 |
SC 13G
| ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 8.8% stake in Rezolute Inc. |
| 06/17/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
|